Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
Neuropeptide

Cerebrolysin — Porcine-Brain Neuropeptide Preparation

Research evidence summary

also known as FPF-1070

Cerebrolysin is a porcine-brain peptide mixture used for stroke, dementia and brain injury in some countries. Trial results, a 2023 Cochrane review, doses in mL, and risks.

Sequence
Complex mixture of low-molecular-weight peptides and amino acids
MW
Mixture of peptides and amino acids
Discovered
1950s-1970s
Receptor
Not a single-receptor drug; a mixture with reported neurotrophic and neuroprotective activity in preclinical models
Half-life
Not established in humansNo source checked
Routes in study
IM, IV
Save

What is Cerebrolysin?

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain (PMID 37818733). It is dosed as a volume of the solution, in mL, not in milligrams. A 2021 review says it is not approved for use in the USA and is used clinically in over 50 countries (PMID 33515100). The 2023 Cochrane review says it is widely used for acute ischaemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries (PMID 37818733).

How does it work?

The mechanism is not settled. The trial reports and reviews describe neuroprotective and neurotrophic properties in preclinical models of ischaemia (PMID 22282884), and a 2021 review outlines signalling pathways it is said to stimulate while saying much remains to be elucidated about its efficacy for specific conditions (PMID 33515100). A 2002 study in cultured rat PC12 cells reported that Cerebrolysin reduced apoptotic cells from 32% to 10% at 100 µg/ml (PMID 12124658). Cell and animal findings are not evidence of benefit in people.

What has been studied in people?

Acute stroke

StudyWho and doseReported result
CASTA, Heiss 2012 (PMID 22282884)1,070 adults with acute ischaemic hemispheric stroke (529 Cerebrolysin, 541 placebo), randomised within 12 hours; 30 mL daily by intravenous infusion for 10 days, with aspirin 100 mg daily; followed for 90 daysThe primary end point, a combined test of the modified Rankin Scale, Barthel Index and NIHSS (a stroke severity score), showed no significant difference; the authors call the result neutral. A post hoc analysis in patients with NIHSS above 12 showed "a trend in favor of Cerebrolysin" (odds ratio 1.27 on both scales, lower confidence bounds 0.97 and 0.90) and, in that subgroup, 90-day mortality of 20.2% on placebo and 10.5% on Cerebrolysin (hazard ratio 1.9661, lower confidence bound 1.0013); the authors say this observation needs confirming in a further trial
Ladurner 2005 (PMID 15583955)146 people with acute stroke; 50 mL daily intravenously for 21 daysNo significant improvement in the Canadian Neurological Scale, Barthel Index or Clinical Global Impressions; a significant improvement on a cognitive test, the Syndrome Short Test
CARS, Muresanu 2016 (PMID 26564102)208 people in early rehabilitation, treated from 24 to 72 hours after stroke; 30 mL daily intravenously for 21 daysPrimary end point, Action Research Arm Test (arm and hand function) on day 90: Mann-Whitney estimator 0.71, P<0.0001, favouring Cerebrolysin. The authors call the trial exploratory with a relatively small sample

A 2018 meta-analysis of nine placebo-controlled stroke trials, using 30 to 50 mL daily for 10 to 21 days, reported better NIHSS scores on day 30 (Mann-Whitney 0.60, N = 1,879) and "safety aspects were comparable to placebo" (PMID 29248999). A 2021 European guideline on pharmacological support in early motor rehabilitation recommends Cerebrolysin 30 mL a day intravenously for at least 10 days (PMID 34152062).

The 2023 Cochrane review of Cerebrolysin and Cerebrolysin-like agents in acute ischaemic stroke included seven randomised trials (1,773 people, one trial of a similar product, Cortexin, among them). It found moderate-certainty evidence of little to no difference in all-cause death (risk ratio 0.96, 95% CI 0.65 to 1.41; 6 trials) and, for Cerebrolysin, an increase in non-fatal serious adverse events (risk ratio 2.39, 1.10 to 5.23; 3 trials, 1,335 people). In the 30 mL for 10 days schedule the increase was larger (risk ratio 2.87, 1.24 to 6.69; 2 trials, 1,189 people). It rated two studies at high risk of other bias and notes that the manufacturer supported three multicentre studies (PMID 37818733).

Alzheimer's disease and vascular dementia

  • Panisset 2002. 192 people with Alzheimer's disease; 30 mL intravenously five days a week for four weeks. At week 12 the global rating (CIBIC+) was significantly better on Cerebrolysin. Adverse events were recorded in 73% of the placebo group and 64% of the Cerebrolysin group; headache, dizziness, weight loss and anxiety were the most common (PMID 12111446).
  • Ruether 2001. 149 people; 30 mL intravenously five days a week for four weeks, repeated after a 2-month break. At week 16 the ADAS-cog (a dementia cognitive rating scale) difference was 3.2 points in favour of Cerebrolysin (P < 0.0001); adverse events were recorded in 43% and 38% (PMID 11552768). An erratum to this paper was published (Int Clin Psychopharmacol 2001;16:372) and it may change these figures, which are those of the original abstract.
  • Alvarez 2006. 279 people given 10, 30 or 60 mL, or placebo, intravenously five days a week for four weeks then twice a week for eight weeks. At week 24 cognition improved significantly only at 10 mL (P=0.038); the authors describe a reversed U-shaped dose-response (PMID 16420392).
  • Pooled analyses. A 2015 meta-analysis of six trials of 30 mL a day in mild-to-moderate Alzheimer's disease reported better cognition at 4 weeks (not significant at 6 months) and better global clinical change at 4 weeks and 6 months (PMID 25832905). A 2009 narrative drug review (not a Cochrane review) concluded Cerebrolysin is "a useful addition to the treatment options available for dementia" and called for longer trials; it lists dizziness or vertigo as the most frequent adverse event (PMID 19848437).
  • Vascular dementia. A 2019 Cochrane review of six trials (597 people) found a small benefit on cognition (very low-quality evidence), said the effects may be too small to be clinically meaningful, and called the supporting evidence base weak (PMID 31710397).

Brain injury and other uses

  • Traumatic brain injury. CAPTAIN I (46 people) gave 50 mL daily for 10 days, then two cycles of 10 mL daily for 10 days; the primary combined end point just missed significance in the intention-to-treat analysis and was significant in the per-protocol analysis (PMID 31494820). CAPTAIN II (142 people, same schedule) reported a small-to-medium effect at day 90 (PMID 31897941).
  • Intramuscular use. A randomised trial in 250 people with smell and taste loss after COVID-19 gave 5 mL intramuscularly five days a week for 8 to 24 weeks; the comparison group did training only with no injection, and complete recovery was reported in 61.5% of 130 analysed on Cerebrolysin and none with training alone (PMID 37950370). A retrospective comparison in 50 people gave 10 mL a day intramuscularly for over 30 days to 23 of them, with 27 controls, for post-stroke spasticity (PMID 29075344). A randomised trial in 50 children aged 18 to 75 months with cerebral palsy gave 0.1 cc/kg intramuscularly daily for 10 days, then weekly for 4 months, and reported a lower (better) mean gross motor function level than the control group (2.1 against 3.16) (PMID 28074392).
  • Healthy volunteers. A 1998 study in 48 men gave 10, 30 or 50 mL, or placebo, daily for 10 days and measured EEG and short-term word recall during hyperventilation, a laboratory model of reduced brain blood flow. It reported a trend towards poorer recall in the placebo group during the first 4 hours that was not seen with Cerebrolysin (PMID 9700674).

A 2021 review of the stroke, dementia and brain injury literature found inconsistent results, with several studies suggesting minor clinical relevance (PMID 33515100). No half-life is known: the product is a mixture, so no single half-life applies.

What are the risks?

  • Non-fatal serious adverse events in stroke. The 2023 Cochrane review reports a potential increase, larger with 30 mL for 10 days (PMID 37818733). CASTA's published abstract says adverse events were documented to assess safety but gives no counts, and the trial's registry record (NCT00868283) had no posted results on 6 November 2026.
  • Common adverse events. Dizziness or vertigo was the most frequently reported in a 2009 review, and headache, dizziness, weight loss and anxiety in the Panisset trial (PMID 19848437, PMID 12111446). Many single-patient case reports of its use in stroke, brain injury and aphasia exist (PubMed, cerebrolysin[tiab] AND case reports[pt], 6 November 2026: 26 records), which are not a basis for judging benefit or safety.
  • Higher doses. In the 1998 healthy-volunteer study, signs of overdosage occurred with the highest dose, 50 mL; the authors describe them as mild, and the highest dose caused a small but significant fall in blood pressure (PMID 9700674).
  • Anaphylaxis. A 2024 case report describes a severe, life-threatening anaphylactic reaction in an 85-year-old man with subacute stroke after intravenous Cerebrolysin, confirmed by laboratory tests; the authors say only rare cases have been published (PMID 39055722).

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Frequently Asked Questions

Has Cerebrolysin been tested with Semax? A PubMed search on 6 November 2026 for cerebrolysin[tiab] AND semax[tiab] returned 2 records: a 2002 rat cell-culture study that compared them and found Semax produced no trophic effect on those cells (PMID 12124658), and a 2026 Russian expert council resolution on ADHD that lists them as separate medicines (PMID 42910684). Neither is a human trial of the two together. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) does not name Cerebrolysin on either of its lists; its entry for Semax (heptapeptide) is on the Semax page. See the Cerebrolysin + Semax evidence review.


Regulatory and clinical status

UK status: A 2021 review says it is not approved for use in the USA and is used clinically in over 50 countries. The 2023 Cochrane review says it is widely used for acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries.

Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

Muresanu DF, Heiss WD, Hoemberg V, et al. (CARS Investigators) · Stroke · 2016, 47(1), 151-9

Randomised controlled trialEvidence weight: moderate
Model
Humans — people in early rehabilitation after stroke, treatment started 24 to 72 hours after onset
Sample size
n = 208 randomised (104 Cerebrolysin, 104 placebo)
Compound(s)
Cerebrolysin
Route in study
Intravenous, 30 mL a day for 21 days, with a standardised rehabilitation programme
Outcome measured
Action Research Arm Test (ARAT) score on day 90 (primary); 12 other outcome scales for global status
Main finding
ARAT on day 90: Mann-Whitney estimator 0.71 (95% CI 0.63-0.79; P<0.0001) favouring Cerebrolysin. Global status across 12 scales: 0.62 (0.58-0.65). The authors call the trial exploratory with a relatively small sample size.
Key limitation
Exploratory trial with a relatively small sample; the authors say results should be confirmed in a large randomised trial.
PubMed PMID:26564102

Reported in study context only — not a recommendation or protocol.

  1. Heiss WD, Brainin M, Bornstein NM, et al.. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.. Stroke. 2012;43(3) :630-6 doi:10.1161/STROKEAHA.111.628537 · PMID: 22282884
  2. Ladurner G, Kalvach P, Moessler H, et al.. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.. Journal of neural transmission (Vienna, Austria : 1996). 2005;112(3) :415-28 doi:10.1007/s00702-004-0248-2 · PMID: 15583955
  3. Ziganshina LE, Abakumova T, Nurkhametova D, et al.. Cerebrolysin for acute ischaemic stroke.. The Cochrane database of systematic reviews. 2023;10(10) :CD007026 doi:10.1002/14651858.CD007026.pub7 · PMID: 37818733
  4. Bornstein NM, Guekht A, Vester J, et al.. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2018;39(4) :629-640 doi:10.1007/s10072-017-3214-0 · PMID: 29248999
  5. Beghi E, Binder H, Birle C, et al.. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke.. European journal of neurology. 2021;28(9) :2831-2845 doi:10.1111/ene.14936 · PMID: 34152062
  6. Alvarez XA, Cacabelos R, Laredo M, et al.. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.. European journal of neurology. 2006;13(1) :43-54 doi:10.1111/j.1468-1331.2006.01222.x · PMID: 16420392
  7. Panisset M, Gauthier S, Moessler H, et al.. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.. Journal of neural transmission (Vienna, Austria : 1996). 2002;109(7-8) :1089-104 doi:10.1007/s007020200092 · PMID: 12111446
  8. Ruether E, Husmann R, Kinzler E, et al.. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.. International clinical psychopharmacology. 2001;16(5) :253-63 doi:10.1097/00004850-200109000-00002 · PMID: 11552768
  9. Gauthier S, Proaño JV, Jia J, et al.. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dementia and geriatric cognitive disorders. 2015;39(5-6) :332-47 doi:10.1159/000377672 · PMID: 25832905
  10. Cui S, Chen N, Yang M, et al.. Cerebrolysin for vascular dementia.. The Cochrane database of systematic reviews. 2019;2019(11) doi:10.1002/14651858.CD008900.pub3 · PMID: 31710397
  11. Fiani B, Covarrubias C, Wong A, et al.. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(4) :1345-1353 doi:10.1007/s10072-021-05089-2 · PMID: 33515100
  12. Poon W, Matula C, Vos PE, et al.. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020;41(2) :281-293 doi:10.1007/s10072-019-04053-5 · PMID: 31494820
  13. Muresanu DF, Florian S, Hömberg V, et al.. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020;41(5) :1171-1181 doi:10.1007/s10072-019-04181-y · PMID: 31897941
  14. Hamed SA, Ahmed MAA. The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post-covid-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: a randomized clinical trial.. Expert review of clinical pharmacology. 2023;16(12) :1261-1276 doi:10.1080/17512433.2023.2282715 · PMID: 37950370
  15. Martinez RM. Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation.. Journal of medicine and life. 2017;10(3) :161-166 · PMID: 29075344
  16. Funke M, Fiehler J, Mewes I, et al.. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.. Journal of neural transmission. Supplementum. 1998;53 :385-98 doi:10.1007/978-3-7091-6467-9_34 · PMID: 9700674
  17. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia.. Drugs & aging. 2009;26(11) :893-915 doi:10.2165/11203320-000000000-00000 · PMID: 19848437
  18. Lapochkin OL, Zykov VP, Zavadenko NN, et al.. [Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2026;126(9. Vyp. 2) :126-135 doi:10.17116/jnevro2026126092126 · PMID: 42910684
  19. Safarova ER, Shram SI, Grivennikov IA, et al.. Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma.. Bulletin of experimental biology and medicine. 2002;133(4) :401-3 doi:10.1023/a:1016270626439 · PMID: 12124658
  20. Nasiri J, Safavifar F. Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial.. Acta neurologica Belgica. 2017;117(2) :501-505 doi:10.1007/s13760-016-0743-x · PMID: 28074392
  21. Trimmel H, Tauber W, Zikeli M. Life-Threatening Anaphylaxis due to Cerebrolysin®.. Case reports in neurological medicine. 2024;2024 :2332908 doi:10.1155/2024/2332908 · PMID: 39055722
Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: unsupported dosing and preparation instructions were removed; the two stroke trials' names, swapped, were corrected and CASTA's neutral result restated; the 2023 Cochrane safety finding was added; legal text was replaced.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Research combinations referencing Cerebrolysin

Combination evidence reviews on this site that include Cerebrolysin as one of their peptides.

Continue reading